
==== Front
J Chest Surg
J Chest Surg
Journal of Chest Surgery
2765-1606
2765-1614
The Korean Society for Thoracic and Cardiovascular Surgery

38584375
10.5090/jcs.24.003
jcs-57-5-492
Case Report
Malignant Solitary Fibrous Tumor of the Mediastinum with Multiple Recurrences and a Rare Metastasis to the Thyroid Gland: A Case Report
https://orcid.org/0000-0002-5167-3454
Yun Ju Sik M.D. 1
https://orcid.org/0000-0002-2084-8143
Song Sang Yun M.D., Ph.D. 1
https://orcid.org/0000-0003-0923-1414
Na Kook Joo M.D., Ph.D. 1
https://orcid.org/0000-0001-9394-4980
Oh Sang Gi M.D., Ph.D. 2
https://orcid.org/0000-0002-9619-7439
Ko Haein M.D. 2
1 Department of Thoracic and Cardiovascular Surgery, Chonnam National University Hwasun Hospital, Chonnam National University School of Medicine, Hwasun, Korea
2 Department of Thoracic and Cardiovascular Surgery, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Korea
Corresponding author Sang Yun Song Tel 82-61-379-7663 Fax 82-61-379-7665 E-mail sysong@jnu.ac.kr ORCID https://orcid.org/0000-0002-2084-8143
5 9 2024
8 4 2024
8 4 2024
57 5 492495
8 1 2024
31 1 2024
5 2 2024
Copyright © 2024, The Korean Society for Thoracic and Cardiovascular Surgery
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Solitary fibrous tumors (SFTs) are rare neoplasms arising from mesenchymal cells. Although most SFTs are benign, rare cases of metastasis have been reported at various sites. Complete surgical resection is the mainstay of treatment for both primary and recurrent or metastatic SFTs. Herein, we present a case of an SFT initially identified in the anterior mediastinum that later developed multiple metastases, even to the thyroid gland. The patient underwent repeated surgical resection and is currently being followed up in an outpatient setting.

Malignant solitary fibrous tumor
Neoplasm metastasis
Thyroid gland
Case reports
Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
==== Body
pmcCase report

A 58-year-old man presented to the hospital with complaints of exertional shortness of breath that had begun 2 weeks earlier. He had a history of hypertension and chronic obstructive pulmonary disease, but there were no notable findings on physical examination or in laboratory tests. A chest radiograph taken upon admission revealed a mass-like opacity in the left hilar region, although the left hilar vessels were still discernible (Fig. 1A). Further investigation with contrast-enhanced computed tomography (CT) showed a heterogeneously enhancing mass with smooth borders in the anterior (prevascular) mediastinum, and a distinct tubular vascular structure within the mass was noted (Fig. 1B). There was no evidence of mediastinal or hilar lymphadenopathy. The patient underwent a transthoracic needle biopsy, which yielded only fragments of fibrocollagenous tissue and was inadequate for a definitive diagnosis. Consequently, surgical intervention was planned for both diagnostic and therapeutic purposes. The patient underwent resection of the mediastinal tumor and a total thymectomy via sternotomy. The excised specimen was a well-encapsulated, yellowish mass measuring 10×6×6 cm, with areas of hemorrhage and necrosis. Histopathological examination and immunohistochemical staining confirmed the diagnosis of a malignant solitary fibrous tumor (SFT). The patient’s recovery after surgery was smooth, and he was discharged in good clinical condition.

The patient was followed up on an outpatient basis at 6-month intervals for 2 years and annually thereafter. Eight years after the initial follow-up, the patient reported a palpable mass on the left side of his back. A 3.5-cm mass with heterogeneous contrast enhancement was detected on chest magnetic resonance imaging (Fig. 2A). The patient underwent surgical excision of the mass in the orthopedics department, which was confirmed to be a metastatic SFT. The patient continued with follow-up care. One year later, a 2-cm, well-defined, round nodule in the superior segment of the left lower lobe was identified on a follow-up chest CT scan (Fig. 2B). The patient underwent wedge resection of the left lower lobe via video-assisted thoracic surgery, and the presence of metastatic SFT was confirmed once more. Four years later, which was 13 years after the initial surgery, the patient presented with swelling in the left neck. A 5.3-cm, well-defined, heterogeneously enhancing mass within the left thyroid gland was revealed on a neck CT scan (Fig. 2C). An ultrasound-guided needle biopsy of the lesion led to a diagnosis of metastatic SFT. The patient then underwent total thyroidectomy in the endocrine surgery department and had an uncomplicated recovery (Fig. 3A). A microscopic examination of the thyroid lesion showed spindle- to pleomorphic-shaped cells arranged in fascicles with a perivascular pattern, mirroring the characteristics of the previous mediastinal lesion (Fig. 3B). Tumor cells from the thyroid lesions also exhibited strong immunopositivity for CD34, STAT-6, and BCL-2 (Fig. 3C–E). Taking into account the clinical and pathological findings, the final diagnosis was a thyroid metastasis originating from the malignant SFT of the mediastinum.

The patient remains in outpatient follow-up and has remained tumor-free for 3 years since the thyroid surgery.

The patient provided written informed consent for publication of his clinical details and images.

Discussion

SFTs are rare neoplasms that originate from mesenchymal cells, most commonly found in the pleura. While the majority of SFTs grow slowly and are benign, they carry a significant risk of metastasis—reported to be between 35%–45%, with even higher rates observed in studies with extended follow-up periods [1]. Malignant SFTs are histologically characterized by high cellularity, nuclear atypia, a mitotic count exceeding 4 mitoses per 10 high-power fields (HPFs), and the presence of necrosis [2]. However, these histological criteria are not absolute predictors of behavior, as metastases can occur even in patients with SFTs that appear benign under the microscope. Given the challenges in prognostication, numerous researchers have investigated and identified various clinical and histological factors that influence outcomes [3,4]. The French Sarcoma Group, in a multicenter cohort study, developed a risk calculator that highlighted key prognostic factors for local recurrence (visceral localization, radiotherapy, and age), metastasis (mitotic count >4/10 HPFs, non-limb tumor localization, and age ≥60 years), and overall survival (age and mitotic count) [4]. Despite these efforts, no clinicopathological factors have yet been found to precisely predict the prognosis for SFTs. Metastases from SFTs most frequently affect the lungs and pleura, but they have also been documented in a range of other organs [3-5]. O’Neill et al. [5] described the metastatic patterns of SFTs, noting that the primary tumor’s location influenced the metastatic sites, with the lungs and pleura being the most common. They also found that patients with extrathoracic SFTs had a higher statistical likelihood of developing metastatic disease compared to those with thoracic SFTs [5]. In a case similar to ours, Ricciuti et al. [6] documented a rare instance of a giant pleural SFT that metastasized to the thyroid gland a year after complete resection. This case underscores the critical role of surgery, even for patients with isolated metastatic disease [6].

Most recurrences or metastases of SFTs occur within 5 years following radical treatment; however, instances of recurrence have been documented even after 10 or 20 years. A recent case report described the successful treatment of a malignant SFT that recurred in the bilateral pleural cavities 17 years after the initial resection of the primary tumor. The treatment involved a staged reoperation, and the authors emphasized that complete, repeated resection of the recurrent tumor is the optimal therapy for improving patient outcomes [7]. Park et al. [8] described a case where 6 surgical resections were carried out for 6 recurrent SFTs over a 24-year period. Based on this experience, the authors advocate for long-term clinical follow-up for all patients with SFTs and endorse repeated complete resections for recurrences of the disease.

Chemotherapy may be considered for cases of dedifferentiated or metastatic SFTs. Park et al. [9] suggested that conventional chemotherapy, such as doxorubicin-based or gemcitabine-based therapy, could be effective in controlling or stabilizing locally advanced and metastatic SFTs. However, the role of chemotherapy has not been clearly established, and its use, including in neoadjuvant and adjuvant treatments, is not standardized. Currently, the treatment of choice for SFT is surgical resection with the aim of complete removal. Recent studies have reported a 10-year overall survival rate of over 70%, and aggressive surgical resection is recommended, even for recurrent lesions [10].

We report our experience with the successful surgical treatment of an SFT that recurred multiple times in the back, lung, and thyroid gland (an exceptionally rare lesion). Our case indicates that SFTs necessitate long-term follow-up exceeding 10 years. Surgical resection, including that of metastatic lesions, is recommended when complete removal is feasible.

Article information

Fig. 1 First preoperative chest radiograph showing a mass lesion in the left hilar area (A); chest computed tomography image demonstrating a heterogeneously enhancing mass in the anterior mediastinum (arrow) (B).

Fig. 2 Chest magnetic resonance imaging (left back, arrow) (A), chest computed tomography (CT) (lower lobe of the left lung, arrow) (B), and neck CT (left thyroid gland, arrow) (C) images at 8, 9, and 13 years after surgery, respectively, showing recurrent solitary fibrous tumor.

Fig. 3 Gross photograph of the thyroidectomy specimen (A), histopathologic findings of the mass (hematoxylin and eosin staining, ×200) (B), and immunohistochemical staining for CD34 (C), STAT-6 (D), and BCL-2 (E).

Author contributions

Conceptualization: JSY, SYS, KJN. Data curation: JSY. Formal analysis: JSY, HK. Methodology: JSY, SYS, KJN. Project administration: KJN, SGO. Visualization: JSY, KJN, HK. Writing–original draft: all authors. Writing–review & editing: all authors. Final approval of the manuscript: all authors

Conflict of interest

No potential conflict of interest relevant to this article was reported.
==== Refs
References

1 Martin-Broto J Mondaza-Hernandez JL Moura DS Hindi N 2021 A comprehensive review on solitary fibrous tumor: new insights for new horizons Cancers (Basel) 13 2913 https://doi.org/10.3390/cancers13122913 10.3390/cancers13122913 34200924
2 Guo W Xiao HL Jiang YG 2011 Retrospective analysis for thirty-nine patients with solitary fibrous tumor of pleura and review of the literature World J Surg Oncol 9 134 https://doi.org/10.1186/1477-7819-9-134 10.1186/1477-7819-9-134 22014289
3 Reisenauer JS Mneimneh W Jenkins S 2018 Comparison of risk stratification models to predict recurrence and survival in pleuropulmonary solitary fibrous tumor J Thorac Oncol 13 1349 62 https://doi.org/10.1016/j.jtho.2018.05.040 10.1016/j.jtho.2018.05.040 29935303
4 Salas S Resseguier N Blay JY 2017 Prediction of local and metastatic recurrence in solitary fibrous tumor: construction of a risk calculator in a multicenter cohort from the French Sarcoma Group (FSG) database Ann Oncol 28 1979 87 https://doi.org/10.1093/annonc/mdx250 10.1093/annonc/mdx250 28838212
5 O'Neill AC Tirumani SH Do WS 2017 Metastatic patterns of solitary fibrous tumors: a single-institution experience AJR Am J Roentgenol 208 2 9 https://doi.org/10.2214/AJR.16.16662 10.2214/AJR.16.16662 27762594
6 Ricciuti B Metro G Leonardi GC 2016 Malignant giant solitary fibrous tumor of the pleura metastatic to the thyroid gland Tumori 102 2_suppl S16 21 https://doi.org/10.5301/tj.5000514 10.5301/tj.5000514 27133228
7 Kovacs T Waxman J 2019 Recurrence of a malignant solitary fibrous tumor of the pleura 17 years after primary tumor resection: a case report Respir Med Case Rep 28 100895 https://doi.org/10.1016/j.rmcr.2019.100895 10.1016/j.rmcr.2019.100895 31334027
8 Park CK Lee DH Park JY Park SH Kwon KY 2011 Multiple recurrent malignant solitary fibrous tumors: long-term follow-up of 24 years Ann Thorac Surg 91 1285 8 https://doi.org/10.1016/j.athoracsur.2010.08.074 10.1016/j.athoracsur.2010.08.074 21440167
9 Park MS Ravi V Conley A 2013 The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysis Clin Sarcoma Res 3 7 https://doi.org/10.1186/2045-3329-3-7 10.1186/2045-3329-3-7 23663788
10 Bertoglio P Querzoli G Kestenholz P 2023 Surgery for solitary fibrous tumors of the pleura: a review of the available evidence Cancers (Basel) 15 4166 https://doi.org/10.3390/cancers15164166 10.3390/cancers15164166 37627194
